Liberty One Investment Management LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 194,550 shares of the company's stock after acquiring an additional 8,205 shares during the period. Johnson & Johnson comprises about 3.3% of Liberty One Investment Management LLC's holdings, making the stock its 7th biggest position. Liberty One Investment Management LLC's holdings in Johnson & Johnson were worth $32,264,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. Brighton Jones LLC grew its stake in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Hudson Value Partners LLC grew its stake in Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the period. Proficio Capital Partners LLC boosted its holdings in shares of Johnson & Johnson by 22.0% in the 4th quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock valued at $2,885,000 after purchasing an additional 3,594 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $1,339,878,000. Finally, Natural Investments LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $986,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of brokerages have weighed in on JNJ. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Finally, Bank of America reduced their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $171.00.
Get Our Latest Report on Johnson & Johnson
Johnson & Johnson Stock Performance
NYSE JNJ traded down $0.82 on Friday, hitting $156.87. The stock had a trading volume of 7,866,488 shares, compared to its average volume of 8,077,942. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The stock has a market cap of $377.44 billion, a price-to-earnings ratio of 17.45, a P/E/G ratio of 2.14 and a beta of 0.41. The company's 50-day moving average is $153.75 and its two-hundred day moving average is $154.49.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. Johnson & Johnson's dividend payout ratio is 57.84%.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
